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Abstract
Background: Axillary node staging plays an important role in the prognostic evaluation and planning of adjuvant
treatment. Breast cancer stem cells, identified on the basis of CD44+CD24-/low expression, are associated with
metastases and drug resistance. It is therefore important to investigate the proportion of CD44+CD24-/low breast
cancer stem cells for the diagnosis of metastases in axillary nodes.
Methods: Thirty-two ipsilateral axillary lymph nodes were collected from patients diagnosed with invasive breast
cancer. Each lymph node (LN) was divided into two equals – one was examined by H&E staining, while the other
was made into a single cell suspension to study the content of CD44+CD24-/low cells by flow cytometry (FCM). The
relationship was investigated between the content of CD44+CD24-/low cells and metastases in axillary nodes which
were confirmed by histology. Associations were tested using the chi-square test (linear-by-linear association), and
the significance level was set at a value of p < 0.05.
Results: In the 32 axillary nodes, the level of CD44+CD24-/low cells was determined to be between 0 and 18.4%: there
was no presence of CD44+CD24-/low cells in 9 LNs, of which 2 had confirmed metastasis; there were less than 10%
CD44+CD24-/low cells in 12 LNs, of which 6 had confirmed metastasis; and there were more than 10% CD44+CD24-/
low cells in 11 LNs, of which 9 had confirmed metastasis. A higher percentage of detected CD44+CD24-/low cells was
significantly associated with more confirmed LN metastases (p = 0.009).
Conclusions: CD44+CD24-/low breast cancer stem cells might help clinicians to determine the presence of LN
metastases. However, its prognostic value remains unclear, while histological diagnosis is still the gold standard.
Background
Breast cancer stem cells (BCSCs) represent a minor subset
of cells in a breast tumor that is deemed as the driver of
tumor initiation, displaying resistance to drugs and devel-
oping metastatic disease [1]. BCSCs, identified on the basis
of CD44+CD24-/low, Lin expression, could form tumors in
nonobese, diabetic/severe combined immunodeficiency dis-
ease mice with as few as 200 of such cells [2]. The expres-
sion was strongly associated with poor clinical outcome
and other prognostic indicators such as tumor histological
grade, proliferation index, hormonal receptor expressions,
and avian erythroblastosis oncogene B2 overexpression [3].
A high percentage of BCSCs enriched with CD44+CD24-/
low phenotype was found harbored in basal-like tumors [4]
and the phenotype was observed in ‘triple-negative’ breast
cancer that responded poorly to chemotherapy [5]. The
combined expressions with CD44 associated with stem
cell-like characteristics and CD24 related to differentiated
epithelial features [6] as prognostic markers for breast can-
cer however remains controversial.
Positive locoregional LN has long been recognized as
an indicator of regional metastases and, subsequently,
a reservoir for further lymphatic and later visceral
metastases [7-9]. It is well noted that tumor cells with
CD44+CD24-/low expression not only possess malignant
behavior as other tumor cells, but also share with nor-
mal stem cells the capacity for self-renewal [3,10-12].
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In a recent in vitro and in vivo study, a high propor-
tion of BCSCs with CD44+CD24-/low expression was
presented in a model with high lymphatic metastatic
ability [13]. The expression level of BCSCs might high-
light the metastatic potential of the disease in the lym-
phatic system, the major route of breast cancer
metastases.
Regional LN dissection has been regarded as a staging
procedure rather than surgical treatment because it was
not seen to benefit survival. [14,15]. The sentinel lymph
node (SLN) biopsy has modified the need of axillary sur-
gery in the treatment of breast cancer for patients; yet, it
remains a staging procedure but reduces post-operative
morbidity [16]. Accurate staging of ipsilateral LN invol-
vement is, however, the best clinicopathologic prognos-
tic indictor for oncologists to precisely evaluate and
offer breast cancer patients the most suitable adjuvant
therapy. Hematoxylin and eosin (H&E) staining of the
surgical LN samples is still the current gold standard for
diagnosing axillary LN metastasis. However, the process
of creating paraffin-embedded slides involves many
steps, leading to a prolonged wait for pathological
results. In this study, we aimed to investigate the pro-
portion of CD44+CD24-/low BCSCs in axillary LN and
examined the relationship with H&E staining results.
Methods
Patients
The study was approved by the local ethics committee of
the Peking University Shenzhen Hospital. Between April
2008 and April 2009, a total of 32 cases were prospectively
sampled for ipsilateral axillary LNs at the Department of
Breast Surgery of Peking University Shenzhen Hospital.
All patients were diagnosed with invasive breast cancer,
confirmed by histological assessment and were scheduled
for surgery. Women who previously received chemother-
apy or endocrine therapy for breast cancer were excluded
from the trial. The median age of female patients enrolled
into the trial was 42 years (range, 21-69 years).
Antibodies and materials
Mouse-anti-human IgG1-FITC (No. : 11-4714), IgG2b-
PE-CY5 (No. : 15-4031), CD24-FITC (No. : eBioSN3),
CD44-PE-CY5 (No. : IM7), and CD326-PE (No. : 1B7)
were obtained from eBioscience, USA; collagenase III,
fetal bovine serum, and OptilyseC hemolytic agents were
obtained from GIBICO, USA. Flow cytometry: Epics XL,
Beckman Coulter were used.
Preparation of single cell suspension
The entire ipsilateral axillary LNs – swollen and hard in
texture – were obtained from patients after surgical
resection within one hour. Each node was divided into
two equal parts. One was taken for histopathological
examination employing H&E staining, and the other was
prepared for a single cell suspension. Adipose tissue of
the LN was removed using ophthalmic scissors, and the
specimen was washed repeatedly using phosphate buffer
solution (PBS) until the blood was totally removed. The
washed specimen was then placed in a Petri dish which
was put on ice, fixed by ophthalmic scissors, repeatedly
pricked using No. 9 syringe needles and rinsed with small
amounts of PBS until the sample turned filamentous.
After, the specimen was repeatedly stamped using two
tissue forceps and rinsed with small amounts of PBS. The
washing liquid was collected and centrifuged at 1500 r/
min for five minutes. The supernatant was removed and
one ml of PBS was added for re-hanging. Afterward, 3 -
5ml of 0.1% collagenase III was added, and the sample
was placed into a 37 °C water bath for 10-30 minutes,
during which the sample was pipetted once every 5 min-
utes using a 10ml pipette. Fetal bovine serum (FBS) was
then added to a final concentration of 10% and centri-
fuged at 1500 r/min for 5 minutes. Supernatant was
removed and 2ml PBS was added for re-suspension, and
then filtered through 300-mesh stainless steel sieve. The
filtered fluid was added with 0.75ml OptilyseC and left to
stand for 15 minutes. Supernatant was removed after the
fluid was added and centrifuged at 1500 r/min for 5 min-
utes; afterward, PBS was added for cleaning purposes.
Finally, 100ul PBS was added for re-suspension.
Cell mark and flow cytometry test
Antibodies IgG1-FITC 10ul, CD326-PE 10ul, IgG2b-PE-
CY5 10ul and cell suspension 50ul were added into
control EP tubes, while antibodies CD24-FITC 10ul,
CD326-PE 10ul, CD44-PE-CY5 10ul and cell suspension
50ul were added into target EP tubes. The tubes were
incubated at room temperature for 15 minutes in the
shade. Afterward, the tubes were washed with PBS and
500ul PBS was added for re-suspension. The voltage of
the control was reset with CD326-PE/SSC to detect the
proportion of CD44+CD24-/low cells in CD326-positive
cell populations.
Statistical analysis
Chi-square test (linear-by-linear association) was used to
examine the relationship between CD44+CD24-/low cell
contents and the axillary LN metastasis using SPSS for
windows release 13.0 (SPSS Inc., USA). The significance
level was set for p-value less than 0.05.
Results
The mechanical-enzymatic method was employed to
make 32 fresh LN tissue samples into a single cell sus-
pension. The CD44+CD24-/low cell content was detected
using flow cytometry and compared with H&E staining
of paraffin section. In 9 LNs in which CD44+CD24-/low
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cell content was 0%, 2 were confirmed with metastasis.
In 12 LNs where CD44+CD24-/low cell content was
between 0% and 10/%, 6 were confirmed with metasta-
sis. In 11 LNs in which CD44+CD24-/low cell content
was between 10% and 18.4%, 9 were confirmed with
metastasis (Table 1 and figure 1). It can therefore be
concluded that a higher percentage of CD44+CD24-/low
cells detected in axillary LN was significantly associated
with a higher chance of LN metastasis (p = 0.009).
Discussion
Cancer stem cell is an ancient but everlasting topic, where
hypotheses about cancer stem cells existed as early as 100
years ago [17-19] and the discovery of leukemia stem cells
has suggested distinct cell subpopulations [20]. In 1997,
Bonnet et al. isolated CD34CD38 cells in human acute
myeloid leukemia [20]. In recent years, scientists were able
to isolate stem-like cells (tumor initiating cells) from solid
tumors. These findings not only laid the theoretical foun-
dation of cancer stem cells, but also shed light for the
treatment of malignant tumor. For a long time, treatment
strategies for malignancy were mainly aimed at tumor
cells in the proliferation and mitotic phases. This leads
cancer cells into interphase, the main cause of cancer
recurrence and metastasis. Cancer stem cell theory has
changed the traditional treatment strategy for patients and
will one day completely cure malignant tumors [21].
As researchers are able to isolate ESA+ CD44+CD24-/low
LIN- cells from breast cancer tissues [3], more and more
studies on BCSCs have appeared, particularly on CD44+
CD24-/low cell’s clinical correlation. However, there is little
research about its clinical value. The mechanical-enzy-
matic method was employed to transform 33 fresh LN tis-
sue samples into a single cell suspension, the CD44+
CD24-/low cell content was then detected using flow cyto-
metry and compared with H&E stained paraffin section to
explore the relationship between CD44+CD24-/low cell
content and LN metastasis.
Process of breast cancer metastasis to axillary LNs
Invasive breast cancer cells first invade lymphatic vessels
and then travel to local LNs through the lymphatic flow
system. The first involved nodes are one or a few pectoral
LNs, known as SLN. In the LNs, cancer cells first cluster
in marginal sinus, then accumulate in the entire LN. This
causes LNs to swell and harden, appearing gray in sec-
tions. Sometimes, tumor tissues invade capsules and
cause several LNs to merge together. After regional LN
metastasize, tumor cells continue to transfer to the next
nodes, eventually entering the blood vessel through the
thoracic duct and secondary metastasis might occur [22].
Contamination of blood cells, cell debris and other parti-
cles in a single cell suspension may cause nonspecific
bindings and influence the result. They may be wrongly
labeled by fluorescent monoclonal antibodies, resulting in
non-specific binding and thus inducing experimental
errors. ESA (CD326), also known as epithelial-specific
antigen (EpCAM), is cell surface glycoprotein of 40Kda in
weight. It’s a broad spectrum marker of epithelial cells
[23]. In our study, we employed CD326 (ESA) / SS instead
of FS / SS as a means of determining ESA-positive cells
and to decrease the influence of cell debris and blood
cells. After the detection scheme was established, we
tested the scheme using breast cancer cell lines and deter-
mined the preliminary parameters to minimize experimen-
tal errors. In our study, the specificity of epithelial cell
marker CD326 was about 80%. Normal lymphoid tissue
may still contain a small amount of other endothelial cells
after processing; therefore, false positive results may still
arise during the measurement of CD44+CD24-/low cell
contents when representing the proportion of BCSCs in
axillary LN metastasis. A low proportion of breast cancer
cells present in LNs may also result in the absence of spe-
cific binding with CD326 monoclonal antibody and in
turn, the accuracy of detecting CD44+CD24-/low cell con-
tents in SLN was reduced.
Relationship of CD44+CD24-/low cell content and axillary
LN metastasis
In 2005, Abraham BK et al. confirmed the proportion of
CD44+CD24-/low cells was associated with distant metasta-
sis using immunohistochemical staining [24]. In 2008,
Ling LJ et al. confirmed that a tumor having a higher pro-
portion of CD44+CD24-/low cells is more prone to bone
metastasis using animal models [25]. It was therefore pos-
tulated that the content of CD44+CD24-/low cells or, in
other words, the proportion of BCSCs might be related to
tumor aggressiveness and distant metastasis, but the rela-
tionship with axillary LN status was not well established.
It is possibly because lymphatic circulation is slower and




Number of axillary lymph
nodes
Metastases confirmed in paraffin
sections
Percentage of positive axillary lymph node
(%)
0 9 2 22.2
0ï½ž10 12 6 50.0
10ï½ž18.4 11 9 81.8
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shorter than blood circulation and, in addition to invasive
stem cells, non-stem cells can also metastasize to ipsilat-
eral axillary LNs. Compared to stem cells, non-stem cells
have a smaller chance of metastasizing according to their
weaker degree of aggressiveness. It was speculated that
distant metastasis of breast cancer is mainly caused by
stem cells.
Diagnosis value of CD44+CD24-/low cells in axillary LN
metastases
Currently, common LN micro-metastasis markers of
breast cancer are human mammaglobin (hMAM) and
adhesion protein 1, where hMAM is known to have high
specificity and sensitivity. Marchetti A et al.[26] detected
LNs using the real-time polymerase chain reaction (RT-
PCR) laboratory technique, and only hMAM and CEA
mRNA were not detected in LNs of healthy individuals,
therefore concluding that the above two markers have
high specificity. Mitas M et al. [27] demonstrated that
hMAM was over-expressed in 16/17 pathology-negative
LNs, suggesting that it could be used as marker of breast
cancer micrometastases in LNs. Mucin, a Mucin 1 mRNA
encoding product, is a membrane glycoprotein with trans-
membrane domain. Mucin 1 has become an indicator of
LN micrometastasis in breast cancer patients. Hao XB
et al. [28] found that mucin 1 mRNA was expressed in the
Figure 1 Typical content of CD44+CD24-/low cells in axillary LNs A and B: With micro-metastasis; C and D: Absent of micro-metastasis
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LNs of all 86 breast cancer patients and RT-PCR did not
show mucin 1 expression in LNs with benign disease.
However, results are inconsistent. Marchetti A et al. [26]
detected the expression of mucin 1 mRNA in healthy LNs,
but with low specificity. These two indicators for LN
metastasis of breast cancer markers may only relate to the
distribution of organs, while CD44+CD24-/low cells not
only relate to the distribution of organs, but also to their
biological characteristics (invasiveness). Compared with
hMAM and mucin 1, CD44+CD24-/low-expressing BCSCs
may have higher false negative and lower false positive
results.
Conclusions
In conclusion, this study suggests that in using CD44+
CD24-/low cells to estimate the metastasis of axillary LNs, a
higher content corresponds to lower false-positive results.
As CD44+CD24-/low double-labeling LN metastases in cell
distribution and function, it may have lower false positive
rates compared to existing markers. Further investigation
on the relationship between the CD44+CD24-/low expres-
sion of tumor cells and LN metastases is warranted. The
detection of BCSCs in LNs may be useful in predicting
micrometastases, especially in sentinel LNs, as a routine
supplementary pathological reference.
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